Thousands eligible for prophylactic tamoxifen on PBS
As many as 50,000 women a year will be eligible for PBS access to tamoxifen for primary prevention of breast cancer, according to figures released by the PBAC.
The selective oestrogen receptor modulator has been approved for five years of PBS-subsidised treatment for women who have a moderate (1.5-3 times higher) or high (three times higher) risk of breast cancer.
Eligibility would be determined by risk calculators and, according to figures released by the PBAC, the drug is expected to be used by 10,000-50,000 women a year at a dose of 20mg daily.
The committee recommended that